Clinical study of 15 cases of primary non-immunodeficient central nervous system lymphoma in children
10.3760/cma.j.cn121090-20230904-00102
- VernacularTitle:15例儿童非免疫缺陷原发中枢神经系统淋巴瘤的临床研究
- Author:
Huixia GAO
1
;
Ningning ZHANG
;
Chunju ZHOU
;
Ling JIN
;
Jing YANG
;
Shuang HUANG
;
Meng ZHANG
;
Nan LI
;
Yonghong ZHANG
;
Yanlong DUAN
Author Information
1. 国家儿童医学中心，首都医科大学附属北京儿童医院儿童肿瘤中心肿瘤内科，儿童血液病与肿瘤分子分型北京市重点实验室，儿童肿瘤国家临床重点专科，儿科重大疾病研究教育部重点实验室，北京 100045
- From:
Chinese Journal of Hematology
2024;45(2):190-194
- CountryChina
- Language:Chinese
-
Abstract:
Clinical data of 15 primary central nervous system lymphoma (PCNSL) children aged ≤18 years admitted to our hospital between May 2013 to May 2023 were retrospectively analyzed. Our goal was to summarize the clinical features of children and investigate the therapeutic effect of a high-dose methotrexate (HD-MTX) based chemotherapy regimen on this disease. The male-to-female ratio was 2.7∶1, and the median age was 7.2 (2.3-16.4) years at diagnosis. The initial clinical symptoms were primarily cranial hypertension, with imaging findings revealing multiple lesions. Pediatric PCNSL with normal immune function has a favorable prognosis with HD-MTX-based chemotherapy. Patients with a stable disease can be treated with minimal or no maintenance. HD-MTX-based chemotherapy remains effective when the disease progresses or recurs after an initial course of non-HD-MTX-based chemotherapy.
